Nanotechnology

Concentrating on CAD with a tumor microenvironment-responsive nano-heterojunction for synergistic induction of cuproptosis and inhibition of colorectal most cancers development | Journal of Nanobiotechnology

novembro 23, 2025
techhdesign


  • Sung H, Ferlay J, Siegel RL, et al. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.


    Google Scholar     

  • Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal most cancers statistics, 2023. CA Most cancers J Clin. 2023;73(3):233–54. https://doi.org/10.3322/caac.21772.


    Google Scholar     

  • Benson AB, Venook AP, Adam M, et al. NCCN pointers® insights: rectal most cancers, model 3.2024. J Natl Compr Canc Netw. 2024;22(6):366–75. https://doi.org/10.6004/jnccn.2024.0041.


    Google Scholar     

  • Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus pointers for the administration of sufferers with metastatic colorectal most cancers. Ann Oncol. 2016;27(8):1386–422. https://doi.org/10.1093/annonc/mdw235.


    Google Scholar     

  • Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-line Nivolumab plus low-dose Ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal most cancers: the part II CheckMate 142 research. J Clin Oncol. 2022;40(2):161–70. https://doi.org/10.1200/JCO.21.01015.


    Google Scholar     

  • Tournigand C, André T, Achille E, et al. FOLFIRI adopted by FOLFOX6 or the reverse sequence in superior colorectal most cancers: a randomized GERCOR research. J Clin Oncol. 2023;41(19):3469–77. https://doi.org/10.1200/JCO.22.02774.


    Google Scholar     

  • Hu S, Dai H, Li T, et al. Broad RTK-targeted remedy overcomes molecular heterogeneity-driven resistance to cetuximab by way of vectored immunoprophylaxis in colorectal most cancers. Most cancers Lett. 2016;382(1):32–43. https://doi.org/10.1016/j.canlet.2016.08.022.


    Google Scholar     

  • Rm J, X Q, Cf L, et al. ARID1A mutations confer intrinsic and purchased resistance to cetuximab remedy in colorectal most cancers. Nature communications. 2022;13(1). https://doi.org/10.1038/s41467-022-33172-5

  • Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The current and way forward for the most cancers dependency map. Nat Rev Most cancers. 2025;25(1):59–73. https://doi.org/10.1038/s41568-024-00763-x.


    Google Scholar     

  • Copur MS, Tun SM, Duckert R. PD-1 blockade in mismatch repair-deficient rectal most cancers. N Engl J Med. 2022;387(9):854–5. https://doi.org/10.1056/NEJMc2209706.


    Google Scholar     

  • Fleischer JR, Schmitt AM, Haas G, et al. Molecular variations of angiogenic versus vessel co-opting colorectal most cancers liver metastases at single-cell decision. Mol Most cancers. 2023;22(1):17. https://doi.org/10.1186/s12943-023-01713-1.


    Google Scholar     

  • Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in most cancers remedy. Sign Transduct Goal Ther. 2023;8(1):293. https://doi.org/10.1038/s41392-023-01536-y.


    Google Scholar     

  • Izci M, Maksoudian C, Manshian BB, Soenen SJ. Using various methods for enhanced nanoparticle supply to stable tumors. Chem Rev. 2021;121(3):1746–803. https://doi.org/10.1021/acs.chemrev.0c00779.


    Google Scholar     

  • Fu L, Zhang Y, Farokhzad RA, Mendes BB, Conde J, Shi J. “Passive” nanoparticles for organ-selective systemic supply: design, mechanism and perspective. Chem Soc Rev. 2023;52(21):7579–601. https://doi.org/10.1039/d2cs00998f.


    Google Scholar     

  • Xue Y, Gao Y, Meng F, Luo L. Latest progress of nanotechnology-based theranostic programs in most cancers therapies. Most cancers Biol Med. 2021;18(2):336–51. https://doi.org/10.20892/j.issn.2095-3941.2020.0510.


    Google Scholar     

  • Andrade F, Rafael D, Vilar-Hernández M, et al. Polymeric micelles focused in opposition to CD44v6 receptor improve niclosamide efficacy in opposition to colorectal most cancers stem cells and scale back circulating tumor cells in vivo. J Management Launch. 2021;331:198–212. https://doi.org/10.1016/j.jconrel.2021.01.022.


    Google Scholar     

  • Téllez T, Martin-García D, Redondo M, García-Aranda M. Clusterin expression in colorectal carcinomas. Int J Mol Sci. 2023;24(19):14641. https://doi.org/10.3390/ijms241914641.


    Google Scholar     

  • Liu Y, Lin Y, Xiao H, et al. mRNA-responsive two-in-one nanodrug for enhanced anti-tumor chemo-gene remedy. J Management Launch. 2024;369:765–74. https://doi.org/10.1016/j.jconrel.2024.04.007.


    Google Scholar     

  • Dutt Y, Pandey RP, Dutt M, et al. Therapeutic functions of nanobiotechnology. J Nanobiotechnol. 2023;21(1):148. https://doi.org/10.1186/s12951-023-01909-z.


    Google Scholar     

  • Yong J, Mellick AS, Whitelock J, Wang J, Liang Ok. A biomolecular toolbox for precision nanomotors. Adv Mater. 2023;35(15):e2205746. https://doi.org/10.1002/adma.202205746.


    Google Scholar     

  • Yang X, Wu H. RAS signaling in carcinogenesis, most cancers remedy and resistance mechanisms. J Hematol Oncol. 2024;17(1):108. https://doi.org/10.1186/s13045-024-01631-9.


    Google Scholar     

  • Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533–52. https://doi.org/10.1038/s41573-020-0068-6.


    Google Scholar     

  • Hitchen N, Williams S, Desai J. Latest advances in therapeutic focusing on of the KRAS pathway in most cancers. Pharmacol Ther. 2025;273:108889. https://doi.org/10.1016/j.pharmthera.2025.108889.


    Google Scholar     

  • Ye W, Lu X, Qiao Y, Ou WB. Exercise and resistance to KRASG12C inhibitors in non-small cell lung most cancers and colorectal most cancers. Biochim Biophys Acta Rev Most cancers. 2024;1879(3):189108. https://doi.org/10.1016/j.bbcan.2024.189108.


    Google Scholar     

  • Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non–small-cell lung most cancers harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120–31. https://doi.org/10.1056/NEJMoa2204619.


    Google Scholar     

  • Maruyama Ok, Shimizu Y, Nomura Y, et al. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal most cancers harboring Her2 amplification and aberrant KRAS localization. NPJ Summary Oncol. 2025;9(1):4. https://doi.org/10.1038/s41698-024-00793-6.


    Google Scholar     

  • Hanrahan AJ, Chen Z, Rosen N, Solit DB. BRAF – a tumour-agnostic drug goal with lineage-specific dependencies. Nat Rev Clin Oncol. 2024;21(3):224–47. https://doi.org/10.1038/s41571-023-00852-0.


    Google Scholar     

  • Ruiz-Saenz A, Atreya CE, Wang C, et al. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. Nat Most cancers. 2023;4(2):240–56. https://doi.org/10.1038/s43018-022-00508-5.


    Google Scholar     

  • Wan Q, Tavakoli L, Wang TY, et al. Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. Nat Commun. 2024;15(1):1442. https://doi.org/10.1038/s41467-024-45852-5.


    Google Scholar     

  • Guo L, Yi X, Chen L, et al. Single-cell DNA sequencing reveals punctuated and gradual clonal evolution in hepatocellular carcinoma. Gastroenterology. 2022;162(1):238–52. https://doi.org/10.1053/j.gastro.2021.08.052.


    Google Scholar     

  • Xie X, Zhang B, Peng J, et al. EGF-upregulated lncRNA ESSENCE promotes colorectal most cancers progress via stabilizing CAD and ferroptosis protection. Analysis. 2025;8:0649. https://doi.org/10.34133/analysis.0649.


    Google Scholar     

  • Li G, Xiao Ok, Li Y, Gao J, He S, Li T. CHIP promotes CAD ubiquitination and degradation to suppress the proliferation and colony formation of glioblastoma cells. Cell Oncol (Dordr). 2024;47(3):851–65. https://doi.org/10.1007/s13402-023-00899-2.


    Google Scholar     

  • Pan J, Zhang M, Rao D, et al. CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, selling HCC metastasis. Hepatology. Printed on-line 2025 March 12 https://doi.org/10.1097/HEP.0000000000001304

  • Ma J, Zhao J, Zhang C, et al. Cleavage of CAD by caspase-3 determines the most cancers cell destiny throughout chemotherapy. Nat Commun. 2025;16(1):5006. https://doi.org/10.1038/s41467-025-60144-2.


    Google Scholar     

  • Wen J, Wen Ok, Tao M, et al. Built-in evaluation reveals an immune evasion prognostic signature for predicting the general survival in sufferers with hepatocellular carcinoma. Most cancers Cell Int. 2025;25(1):101. https://doi.org/10.1186/s12935-025-03743-9.


    Google Scholar     

  • Weinstein JN, Collisson EA, Mills GB, et al. The Most cancers Genome Atlas pan-cancer evaluation mission. Nat Genet. 2013;45(10):1113–20. https://doi.org/10.1038/ng.2764.


    Google Scholar     

  • Jiang L, Qi Y, Yang L, et al. Reworking the tumor immune microenvironment by way of siRNA remedy for precision most cancers remedy. Asian J Pharm Sci. 2023;18(5):100852. https://doi.org/10.1016/j.ajps.2023.100852.


    Google Scholar     

  • Hu F, Huang J, Bing T, et al. Stimulus-responsive copper advanced nanoparticles induce cuproptosis for augmented most cancers immunotherapy. Adv Sci. 2024;11(13):2309388. https://doi.org/10.1002/advs.202309388.


    Google Scholar     

  • Li Ok, Wu L, Wang H, et al. Apoptosis and cuproptosis co-activated copper-based metal-organic frameworks for most cancers remedy. J Nanobiotechnology. 2024;22(1):546. https://doi.org/10.1186/s12951-024-02828-3.


    Google Scholar     

  • Zhang N, Ping W, Rao Ok, et al. Biomimetic copper-doped polypyrrole nanoparticles induce glutamine metabolism inhibition to reinforce breast most cancers cuproptosis and immunotherapy. J Management Launch. 2024;371:204–15. https://doi.org/10.1016/j.jconrel.2024.05.045.


    Google Scholar     

  • He G, Pan Y, Zeng F, et al. Microfluidic synthesis of CuH nanoparticles for antitumor remedy via hydrogen-enhanced apoptosis and cuproptosis. ACS Nano. 2024;18(12):9031–42. https://doi.org/10.1021/acsnano.3c12796.


    Google Scholar     

  • Mao L, Lu J, Wen X, et al. Cuproptosis: mechanisms and nanotherapeutic methods in most cancers and past. Chem Soc Rev. 2025;54(13):6282–334. https://doi.org/10.1039/d5cs00083a.


    Google Scholar     

  • Bao J, Wang J, Chen S, et al. Coordination self-assembled AuTPyP-Cu metal-organic framework nanosheets with pH/ultrasound dual-responsiveness for synergistically triggering cuproptosis-augmented chemotherapy. ACS Nano. 2024;18(12):9100–13. https://doi.org/10.1021/acsnano.3c13225.


    Google Scholar     

  • Choi J, Shin JY, Kim TK, et al. Web site-specific mutagenesis screening in KRAS mutant library to uncover resistance mechanisms to KRASG12D inhibitors. Most cancers Lett. 2024;591:216904. https://doi.org/10.1016/j.canlet.2024.216904.


    Google Scholar     

  • Shi Y, Wu Z, Qi M, et al. Multiscale bioresponses of metallic nanoclusters. Adv Mater. 2024;36(13):e2310529. https://doi.org/10.1002/adma.202310529.


    Google Scholar     

  • Yan N, Wang Y, Wong TY, et al. Differential mapping of intracellular metallic nanoparticles and ions and dynamic modeling prediction. ACS Nano. 2025;19(23):21644–59. https://doi.org/10.1021/acsnano.5c04379.


    Google Scholar